Biodexa 1H26 Results: Going Concern Warning and Nasdaq Delisting Risk
BDRX has more than doubled off its 52-week low of $0.61 on elevated volume (52× avg).
Summary
Biodexa's 1H26 results show a £1.84 million loss, £3.23 million cash balance, and a going concern warning with further financing needed by Q4 2026. The company also faces potential Nasdaq delisting risk.
Key Events · Earnings and Guidance · BDRX
-
Going Concern Material Uncertainty
Directors state further financing will be required during Q4 2026; cash balance of £3.23 million at June 30, 2026, plus $3.5 million raised July 1, 2026, provides only a short runway.
-
Nasdaq Listing Risk
Company's market capitalization is below Nasdaq's proposed $5 million minimum threshold; implementation stayed pending SEC review, but non-compliance could limit financing and strategic options.
-
1H26 Financial Results
Consolidated loss of £1.84 million (1H25: £3.81 million); R&D costs rose 75% to £2.92 million; net cash used in operating activities was £4.61 million.
-
Serenta Phase 3 Enrollment Progress
92 of 168 planned subjects enrolled across 19 US and 10 European centers; two Canadian centers expected to begin enrolling in 4Q26.
Analysis · BDRX · Life Sciences
Biodexa's 1H26 interim results, incorporated into this prospectus supplement, reveal a going concern material uncertainty — further financing is required during Q4 2026, with only £3.23 million in cash at June 30, 2026 plus the $3.5 million raised July 1. The company also faces potential Nasdaq delisting because its market capitalization is below the proposed $5 million minimum threshold. These disclosures materially change the risk profile for existing and prospective shareholders.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 35.7% of the 1694 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.10%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $679.3K. The 52-week trading range was $0.61 to $59.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.